NEWTON, Mass.--(BUSINESS WIRE)--Clinical Data, Inc. (NASDAQ: CLDA), a leader in the development of targeted therapeutics and predictive tests from a growing portfolio of proprietary genetic biomarkers, today announced that it has initiated a long-term safety study for Vilazodone, the company’s drug candidate for the treatment of depression, ahead of schedule. Along with a second pivotal Phase III trial that is on track to begin in the company’s fiscal fourth quarter, ending on March 31, 2008, this safety study is intended to support a new drug application (NDA) for Vilazodone expected to be filed with the U.S. Food & Drug Administration in 2009.
